PubMed Health⌕ Search

Biomedical subjects

Silvina B Tonarelli

Publications and source records attributed to Silvina B Tonarelli.

3 recordsLinked to original sources

What's new in stroke? The top 10 for 2004/05.

During the past decade, stroke has emerged from the dark ages of therapeutic nihilism to the current dawn of treatment activism, fueled by an unprecedented amount of high-quality clinical research. Here, the choices for the "Top 10" studies of 2004/05 influencing the management of patients with stroke and threatened stroke are reviewed. Nine are randomized, clinical trials involving a total of 61,810 participants. Three studies involved intracerebral hemorrhage, an important stroke subtype in which few trials have previously been carried out. Three studies involved acute treatment of stroke, and their results emphasize that "time is brain," and minutes count, in management of acute ischemic and hemorrhagic stroke. The 10th study was a longitudinal cohort analysis of participants with atrial fibrillation pooled from six clinical trials that validated predictive schemes to identify those who benefit most from anticoagulation. The practical management implications of these studies refine and improve care of geriatric patients with cerebrovascular disease.

Anticoagulants↗

Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.

BACKGROUND: Approximately 7000 intracerebral hemorrhages (ICHs) annually in the US are caused by use of antithrombotic therapies. We review the incidence, risk factors, and predictors of ICH in patients receiving long-term anticoagulation or antiplatelet therapy. SUMMARY OF REVIEW: ICH rates range from 0.3% to 0.6% per year during oral anticoagulation in recent reports. Major risk factors are advanced patient age, elevated blood pressure, intensity of anticoagulation, and previous cerebral ischemia. Combining antiplatelet agents with anticoagulation and the combined use of aspirin plus clopidogrel appear to increase ICH risk. Modest blood pressure-lowering halves the frequency of ICH during antiplatelet therapy. CONCLUSIONS: ICH is an uncommon, but often fatal, complication of antithrombotic therapy that particularly afflicts patients with previous stroke. Recent data support that keeping international normalized ratio < or =3.0, control of hypertension, and avoiding the combination of aspirin with warfarin reduce its frequency.

Administration, Oral↗